ATE207355T1 - Behandlung von hyperproliferativen gefässerkrankungen - Google Patents

Behandlung von hyperproliferativen gefässerkrankungen

Info

Publication number
ATE207355T1
ATE207355T1 AT95100194T AT95100194T ATE207355T1 AT E207355 T1 ATE207355 T1 AT E207355T1 AT 95100194 T AT95100194 T AT 95100194T AT 95100194 T AT95100194 T AT 95100194T AT E207355 T1 ATE207355 T1 AT E207355T1
Authority
AT
Austria
Prior art keywords
treatment
vascular diseases
hyperproliferative vascular
mammal
hyperproliferative
Prior art date
Application number
AT95100194T
Other languages
English (en)
Inventor
Robert Ryder Dr Bartlett
Randall E Morris
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Application granted granted Critical
Publication of ATE207355T1 publication Critical patent/ATE207355T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT95100194T 1994-01-13 1995-01-09 Behandlung von hyperproliferativen gefässerkrankungen ATE207355T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/181,116 US5519042A (en) 1994-01-13 1994-01-13 Method of treating hyperproliferative vascular disease

Publications (1)

Publication Number Publication Date
ATE207355T1 true ATE207355T1 (de) 2001-11-15

Family

ID=22662966

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95100194T ATE207355T1 (de) 1994-01-13 1995-01-09 Behandlung von hyperproliferativen gefässerkrankungen

Country Status (10)

Country Link
US (1) US5519042A (de)
EP (1) EP0665013B1 (de)
JP (1) JP2843774B2 (de)
AT (1) ATE207355T1 (de)
AU (1) AU696851B2 (de)
CA (1) CA2140106C (de)
DE (1) DE69523350T2 (de)
DK (1) DK0665013T3 (de)
ES (1) ES2166381T3 (de)
PT (1) PT665013E (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO1996040098A2 (en) 1995-06-07 1996-12-19 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5721277A (en) * 1995-04-21 1998-02-24 Sugen, Inc. Compounds and methods for inhibiting hyper-proliferative cell growth
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
US7611533B2 (en) * 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
DE19539638A1 (de) * 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
DE19547648A1 (de) * 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
DE19610955A1 (de) 1996-03-20 1997-09-25 Hoechst Ag Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
WO1997045105A1 (en) 1996-05-24 1997-12-04 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing diseases of body passageways
US5856330A (en) * 1996-07-31 1999-01-05 Hoechst Aktiengesellschaft Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin
US5981536A (en) * 1996-07-31 1999-11-09 Hoechst Aktiengesellschaft Use of xanthine derivatives for the modulation of apoptosis
US6011051A (en) * 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
US6890546B2 (en) * 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US7691890B2 (en) 1998-03-11 2010-04-06 James W. Williams Anti-viral uses of leflunomide products
AU3080299A (en) * 1998-03-11 1999-09-27 Ohio State University Research Foundation, The Anti-viral uses of leflunomide products
US8029561B1 (en) * 2000-05-12 2011-10-04 Cordis Corporation Drug combination useful for prevention of restenosis
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
US7300662B2 (en) 2000-05-12 2007-11-27 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US20050002986A1 (en) * 2000-05-12 2005-01-06 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
WO2002026139A1 (en) 2000-09-29 2002-04-04 Cordis Corporation Coated medical devices
US20040241211A9 (en) * 2000-11-06 2004-12-02 Fischell Robert E. Devices and methods for reducing scar tissue formation
CA2434972C (en) 2001-01-16 2010-06-08 Vascular Therapies, Llc Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts
EP1842569A3 (de) * 2001-02-16 2010-03-03 Abbott Laboratories Vascular Enterprises Limited Implantate mit FK506
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US20040137066A1 (en) * 2001-11-26 2004-07-15 Swaminathan Jayaraman Rationally designed therapeutic intravascular implant coating
US6641611B2 (en) 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
US20080145402A1 (en) * 2001-09-10 2008-06-19 Abbott Cardiovascular Systems Inc. Medical Devices Containing Rapamycin Analogs
CN1646122A (zh) * 2002-04-16 2005-07-27 藤泽药品工业株式会社 用于预防和/或治疗慢性排斥的药物
US7309349B2 (en) * 2003-01-23 2007-12-18 Cordis Corporation Friction reducing lubricant for stent loading and stent delivery systems
US6894184B2 (en) * 2003-03-18 2005-05-17 Aventis Pharma Deutschland Gmbh Process for preparing 2-cyano-3-hydroxy-N-(phenyl)but-2-enamides
DE10311763A1 (de) * 2003-03-18 2004-10-07 Aventis Pharma Deutschland Gmbh Verfahren zur Herstellung von 2-Cyan-3-hydroxy-N-(phenyl)but-2-enamiden
EP2012861A4 (de) * 2006-04-17 2010-03-10 Hadasit Med Res Service Ptca-führungskatheter mit extralumen zur kontinuierlichen infusion von medikamenten

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
AU7854291A (en) * 1990-04-27 1991-11-27 Rorer International (Holdings), Inc. Styryl compounds which inhibit egf receptor protein tyrosine kinase
IL99811A (en) * 1990-10-30 1996-03-31 Roussel Uclaf 3-cycloalkyl-propanamides their tautomer forms and their salts preparation process and compositions containing them
EP0538783B1 (de) * 1991-10-23 1995-09-27 Hoechst Aktiengesellschaft N-phenyl-2-cyano-3-hydroxycrotonsäureamidderivate und deren Verwendung als Arzneimittel mit immunmodulatorischer Eigenschaft
CA2086642C (en) * 1992-01-09 2004-06-15 Randall E. Morris Method of treating hyperproliferative vascular disease
ES2124800T3 (es) * 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion de interleuquina 1 beta.
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers

Also Published As

Publication number Publication date
AU696851B2 (en) 1998-09-17
JP2843774B2 (ja) 1999-01-06
CA2140106C (en) 2006-12-12
EP0665013A1 (de) 1995-08-02
ES2166381T3 (es) 2002-04-16
CA2140106A1 (en) 1995-07-14
US5519042A (en) 1996-05-21
DE69523350D1 (de) 2001-11-29
AU1015095A (en) 1995-07-20
DK0665013T3 (da) 2002-02-18
EP0665013B1 (de) 2001-10-24
DE69523350T2 (de) 2002-07-04
JPH07277976A (ja) 1995-10-24
PT665013E (pt) 2002-03-28

Similar Documents

Publication Publication Date Title
DE69523350D1 (de) Behandlung von hyperproliferativen Gefässerkrankungen
ATE143263T1 (de) Behandlung von neurodegenerativen erkrankungen
ATE117204T1 (de) Psychostimulierendes mittel.
KR890701107A (ko) 알쯔하이머 병 치료용 화합물들
FI913045A0 (fi) Heterocyklenderivat.
ATE218864T1 (de) Verwendung von piperidin-derivaten in der behandlung von schizophrenie
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
DE69130586D1 (de) Behandlung von Pankreaskrankheit mit 15-keto-Prostaglandin E-Derivaten
ATE137116T1 (de) Behandlung von entzündlichen erkrankungen mit 15- ketoprostaglandinen
ATE84716T1 (de) 4-chinolincarbonsaeure-derivate, brauchbar zur behandlung von haut- und muco-epithelialgewebekrankheiten.
DE68903092D1 (de) Laktamimide in der behandlung arzneiresistenter protozoeninjektionen.
ATE125704T1 (de) Behandlung neurodegenerativer erkrankungen.
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
DE69303234D1 (de) Behandlung von entzündlichen Darmerkrankungen
DE69419954D1 (de) Arzneimittel zur Behandlung von Hauterkrankungen
FI925544A7 (fi) Bentsoehappojohdannaisia leukotrieeniin liittyvien sairauksien hoitami seen
RU94011321A (ru) Способ профилактики и лечения заболеваний кожи
ATE274905T1 (de) 4,5-dihydroxy-2-cyclopentene-1-on für die behandlung von rheumatismus, entzündungen und autoimmunerkrankungen
ATE120447T1 (de) Polyamin-derivate als antineoplastische mittel.
DE69124415D1 (de) Verwendung von 15-Dehydroxy-16-Oxoprostaglandin bei der Behandlung von allergischen Erkrankungen
FI925546A7 (fi) Amidiliittyneitä pyridyylihappojohdannaisia leukotrieeniin liittyvien sairauksien hoitamiseksi
DE69307702D1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
ATE178336T1 (de) Verwendung einer therapeutischen zusammensetzung zur behandlung von bronchitis
DE69619088D1 (de) Quinoxalin-Derivate zur Behandlung von Tinnitus
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification